Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

被引：14

作者：

Abeykoon, Jithma P. ^{[1
]}

Vaxman, Julia ^{[1
]}

Patel, Sanjay V. ^{[2
]}

Kumar, Shaji ^{[1
]}

Malave, Gabriella C. ^{[1
]}

Young, Kimberly S. ^{[1
]}

Ailawadhi, Sikander ^{[3
]}

Larsen, Jeremy T. ^{[4
]}

Dispenzieri, Angela ^{[1
]}

Muchtar, Eli ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Kourelis, Taxiarchis ^{[1
]}

Leung, Nelson ^{[1
]}

Warsame, Rahma ^{[1
]}

Go, Ronald S. ^{[1
]}

Bergsagel, Leif ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Gertz, Morie A. ^{[1
]}

Kapoor, Prashant ^{[1
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[2] Mayo Clin, Dept Ophthalmol, Rochester, MN USA

[3] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Div Hematol, Scottsdale, AZ USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 01期

关键词：

antibody-drug conjugate; B-cell maturation antigen; monoclonal gammopathy; ANTIBODY; DRUG;

D O I：

10.1111/bjh.18298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

引用

页码：95 / 99

页数：5

共 50 条

[41] Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
Yifei Zhang
Amandeep Godara
Stacey Pan
Denis Toskic
Hashim Mann
Douglas Sborov
Raymond Comenzo
Ankit Kansagra
Annals of Hematology, 2022, 101 : 2119 - 2121
[42] Multiple Myeloma Belantamab Mafodotin opens up New Treatment Perspective
Sankawa, Yuri
ACTA HAEMATOLOGICA, 2021, 144 (05) : 592 - 593
[43] A real-world study of belantamab mafodotin in a heavily pretreated population of multiple myeloma patients
Bird, Sarah
Bishop, Ellouise
Panopoulou, Katerina
Saso, Radovan
Mir, Farheen
Stern, Simon
Kaiser, Martin
Boyd, Kevin
Pawlyn, Charlotte
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 60 - 61
[44] Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin
Popat, Rakesh
Badros, Ashraf Z.
Kumar, Shaji
Rodríguez-Otero, Paula
Cohen, Adam D.
Manier, Salomon
Voorhees, Peter M.
Gay, Francesca
Rifkin, Robert M.
Martin, Thomas
Chari, Ajai
Weisel, Katja
Farooq, Asim V.
Jeng, Bennie H.
Chng, Wee Joo
Lee, Hans C.
Berdeja, Jesus
Jadhav, Vinay
Tosolini, Alessandra
Eliason, Laurie
Palumbo, Antonio
Dimopoulos, Meletios A.
Lonial, Sagar
Trudel, Suzanne
Richardson, Paul G.
Terpos, Evangelos
BLOOD, 2021, 138
[45] Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kanellias, Nikolaos
Eleutherakis-Papaiakovou, Evangelos
Roussou, Maria
Psarros, Giorgos
Kastritis, Efstathios
Dimopoulos, Meletios A.
Terpos, Evangelos
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (03) : 502 - 504
[46] EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
Tzogani, Kyriaki
Penttil, Karri
Lahteenvuo, Johanna
Lapvetelainen, Tuomo
Lopez Anglada, Lucia
Prieto, Carolina
Garcia-Ochoa, Blanca
Enzmann, Harald
Gisselbrecht, Christian
Delgado, Julio
Pignatti, Francesco
ONCOLOGIST, 2021, 26 (01): : 70 - 76
[47] Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.
Neupane, Karun
Ehsan, Hamid
Wahab, Ahsan
Masood, Adeel
Ahmed, Tehniat Faraz
Bahram, Saman
Hannan, Abdul
Haider, Mobeen Zaka
Shahzad, Moazzam
Mushtaq, Muhammad Umair
Anwer, Faiz
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
David Gil-Sierra, Manuel
Del Pilar Briceno-Casado, Maria
Javier Julia-Luna, Francisco
Dolores Martinez-Moya, Maria
INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (05) : 373 - 376
[49] Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma
不详
ONCOLOGY-NEW YORK, 2024, 38 (07):
[50] Soluble BCMA in tear fluids: a potential mechanism of ocular toxicity caused by Belantamab mafodotin
Munawar, U.
Theuersbacher, J.
Steinhardt, M.
Zhou, X.
Vogt, C.
Nerreter, S.
Han, S.
Regensburger, A. -K.
Haertle, L.
Teufel, E.
Mersi, J.
Bittrich, M.
Seifert, F.
Haider, M. S.
Einsele, H.
Rasche, L.
Kampik, D.
Kortuem, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 311 - 311

← 1 2 3 4 5 →